On September 30, 2026, Kirsty Maclean and Karthikeyan Devaraju of Cerba Research will host a session focused on synchronizing flow cytometry, genomics, and bioanalytical testing. The discussion centers on moving beyond single-modality assessments to create a cohesive view of cellular phenotype, genetic modifications, and therapeutic potency. By integrating these disparate data streams, developers can better address the unique challenges posed by CAR-T, hematopoietic stem cell, and AAV-based therapies.
Cerba Research Experts to Address CGT Analytical Bottlenecks
Navigating the complexities of cell and gene therapy requires more than isolated testing, as developers struggle to balance rigorous safety standards with evolving regulatory demands. A forthcoming webinar aims to bridge this gap by demonstrating how integrated multi-omic strategies can refine characterization and accelerate clinical development timelines.
Beyond the scientific hurdles, the presenters will tackle the logistical realities of global clinical trials. Ensuring assay standardization and data consistency across international sites remains a primary friction point for sponsors aiming to scale their programs. The session provides a framework for managing these complexities, offering strategies to reduce development risk and streamline the path from molecular design to commercialization.
Comments (0)
No comments yet. Be the first!